GLS-1200 for Infections
This study is evaluating whether a nasal spray may help prevent the spread of a virus that causes SARS.
See full descriptionAbout the trial for Infections
Treatment Groups
This trial involves 2 different treatments. GLS-1200 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether GLS-1200 will improve 2 primary outcomes and 1 secondary outcome in patients with Infections. Measurement will happen over the course of 4 weeks of treatment.
Patient Q & A Section
Who should consider clinical trials for infections?
Patients with a substantial risk of infection should be considered as potential participants in a drug trial for treatment or prophylaxis of infection. Furthermore, patients with a significant likelihood of infection should be considered candidates for a randomized controlled trial of treatments aimed at limiting morbidity or mortality of infection.
How many people get infections a year in the United States?
According to this model 1 infection will cause over 8 million admissions in the United States. Over 12 million people will be hospitalized during a year that includes an influenza epidemic. The data is from a 2002–2005 database for adults and excludes newborns.\n
What are the signs of infections?
Signs of infection include an erythematous, swollen, or tender lymph node, fever, lower-respiratory tract infection, or sepsis. Abnormal signs of infection may include an increased white blood count, pleural effusion, and pleural calcification on radiographic studies.
What is infections?
Infectious diseases are diseases caused by microbes. In an adult the most common infections are viral and bacterial (bacterial and helminthic). Pneumonia is a kind of infectious disease occurring when inhaled viruses are passed into the bloodstream.\n
Can infections be cured?
Infections are not curable, but may be managed by treating the underlying cause and eliminating the infection source. If infection is not manageable by other means, antibiotics may be beneficial in uncomplicated cases for uncomplicated infections, and antibiotics can reduce symptoms and the need for further testing and intervention.
What causes infections?
In common with infections by viruses and bacteria, the cause of many infections is unknown but infectious agents may act either positively or negatively on cells. The immune system may play a major role in some infections, while in others, the cause may be related to cellular damage. Viruses, bacteria, parasitic organisms and the body's immune response may also play a role. To date the most compelling evidence is of an ongoing global immune system response to certain pathogens causing infection. Some infections occur as part of a normal process of infection i.e. they are not a direct cause of disease. Examples are: the immune response to an infection-fighting antibody, or a type of immune response that generates a hypersensitivity reaction such as rheumatoid arthritis.
What are common treatments for infections?
The most common treatments for infections are medications, antibiotics being the most common. It is important that doctors and patients be informed about their treatment-seeking options, including alternatives to the use of medication or antibiotics, as well as the risks and benefits of these therapies.
What is the primary cause of infections?
Infections and malignancies are the most common cause of death. Infectious diseases account for about half of deaths, and malignancies account for two-thirds. [Mortality due to infections and malignancies are significantly higher than the national death rates (9.0% vs. 6.9% from all causes) (ABS 2007-08).] To find active infections and malignancy clinical trials in your area, you can use Power to search by condition, treatment, or location.
Have there been any new discoveries for treating infections?
Infections, though they continue to be the biggest cause of morbidity and mortality in our hospitals, have made very little headway over the past decade.
Does gls-1200 improve quality of life for those with infections?
Recent findings demonstrate that GL-1200 in addition to standard medical management can have a substantial impact on QOL for individuals with infections. Recent findings further demonstrate the importance of incorporating the patient's perspective, in addition to medical expert opinion, when designing and evaluating medical interventions.
Is gls-1200 safe for people?
Gls-1200 was generally well tolerated as a single-dose treatment in an ambulatory setting. It had a rapid onset, with a median time to peak levels of 0.5 hours. It was highly tolerable during all treatment periods, with no serious adverse events. Gls-1200 was safe and well tolerated even when administered as a single-dose treatment at a higher dose than this study was originally designed to evaluate. This trial-sequential decision-making paradigm is appropriate in the context of evaluating a drug regimen under an exploratory, proof-of-concept study design.
What are the common side effects of gls-1200?
As mentioned above, adverse drug reactions associated with the use of the new-generation gls-1200 treatment are similar to those seen previously for gls-100. It is likely that other products on the market will also have similar side effects.